Tag: New Jersey

NORTH BERGEN, NJ, July 16, 2025 (GLOBE NEWSWIRE) -- Free Flow, Inc. (OTC PK: FFLO), which is incorporated in the state of Delaware as Free Flow USA, Inc., today announced that the Company’s Accurate Investments, Inc subsidiary has entered into a contract to purchase a real estate investment property in New Jersey with existing and arranged highly-accredited tenants that would pay an approximate triple net lease amount of over $1,800,000 per annum against long term leases.

NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group," “Aptorum” or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs in oncology  and infectious diseases, and DiamiR Biosciences (“DiamiR”), a developer of proprietary innovative blood-based tests for brain health and other diseases with a CLIA licensed, CAP accredited clinical laboratory in New Haven, CT, today announced that they have entered into a definitive agreement for an all-stock merger transaction, in which DiamiR Biosciences will retain its name and become a wholly-owned subsidiary of Aptorum Group upon consummation of the merger.The combined company expects to remain listed on the Nasdaq Stock Market following the closing of the merger.

NEW YORK and NEW ORLEANS, July 15, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company’s shares between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.

NEW YORK and NEW ORLEANS, July 15, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 22, 2025 to file lead plaintiff applications in securities class action lawsuits against Organon & Co. (NYSE: OGN), if they purchased the Company’s securities between November 3, 2022 and April 30, 2025, inclusive (the “Class Period”). These actions are pending in the United States District Court for the District of New Jersey.